Depot medroxyprogesterone acetate and osteoporosis Monitor serum oestradiol concentration in usersBMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6930.717 (Published 12 March 1994) Cite this as: BMJ 1994;308:717
- A Szarewski,
- B Hollingworth,
- J Guillebaud
- Margaret Pyke Centre, London W1V 6JB
- Department of Obstetrics and Gynaecology, Kettering General Hospital, Kettering NN16 8UZ.
EDITOR, - T Cundy and colleagues again report the theoretical risk of oestrogen deficiency and osteoporosis in long term users of depot medroxyprogesterone acetate.1 Their previous study2 was criticised on methodological grounds,3 and the issue has not yet been resolved. As before, their small study is cross sectional rather than prospective. Once again, we do not know the bone densities of the women before they used depot medroxyprogesterone acetate. In addition, we are not given …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial